-
There are many resources that help health care institutions develop strategies for teaching people how to appropriately access health care and use it to their best interest.
-
Education about skin cancer is still needed, says Linda K. Franks, MD, FAAD, director of Gramercy Park Dermatology in New York City, though it is common to see adults on vacation making little effort to avoid the known risks for skin cancer, which is exposure to ultraviolet radiation.
-
It's time to redouble efforts to stem adolescent pregnancy. Preliminary birth statistics released by the Centers for Disease Control and Prevention indicate the U.S. birth rate rose by 3% between 2005 and 2006 among females 15-19 after dropping 34% between 1991 and 2005.
-
Patients with limited arthritis in their knees typically had to live with pain and discomfort or wait until deterioration reached a point at which they could undergo a total knee replacement, but new technology gives patients a third option that allows them to return to normal activity without pain earlier in their lives.
-
Just 35% of heart attack survivors reported receiving outpatient cardiac rehabilitation services when surveyed by the Centers for Disease Control and Prevention.
-
-
The more scientists and public health officials learn about HIV prevention, the more they realize that targeting specific cultural and demographic groups of people who are not infected is a costly and labor-intensive venture.
-
The Caribbean receives scant attention from HIV researchers and public health officials, and this has resulted in an epidemic that is poorly understood, an investigator says.
-
Over-the-counter contraceptive products that contain the spermicide nonoxynol-9 (N-9) now will carry a warning label to alert consumers that such products do not protect against sexually transmitted diseases (STDs) and HIV/AIDS, following a final ruling by the Food and Drug Administration (FDA).
-
This multicenter, randomized, placebo-controlled trial of a synthetic GHRH analogue, tesamorelin (1-44 amino acids from the amino terminal of GHRH with a trans-3-hexenoyl group added to the amino terminal to increase the half-life over native GHRH), randomized 412 patients (86% male) to daily subcutaneous tesamorelin vs placebo for 26 weeks.
